KR880001609A - 앤지오텐신 ii 수용체 차단 이미다졸 - Google Patents
앤지오텐신 ii 수용체 차단 이미다졸 Download PDFInfo
- Publication number
- KR880001609A KR880001609A KR1019870007464A KR870007464A KR880001609A KR 880001609 A KR880001609 A KR 880001609A KR 1019870007464 A KR1019870007464 A KR 1019870007464A KR 870007464 A KR870007464 A KR 870007464A KR 880001609 A KR880001609 A KR 880001609A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- solvent
- carbon atoms
- formula
- alkyl
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title claims 16
- 102000008873 Angiotensin II receptor Human genes 0.000 title 1
- 108050000824 Angiotensin II receptor Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 78
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract 2
- 206010019280 Heart failures Diseases 0.000 claims abstract 2
- 206010020772 Hypertension Diseases 0.000 claims abstract 2
- 150000002460 imidazoles Chemical class 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 46
- 239000002904 solvent Substances 0.000 claims 45
- 125000004432 carbon atom Chemical group C* 0.000 claims 44
- 125000000217 alkyl group Chemical group 0.000 claims 30
- -1 1-adamantyl Chemical group 0.000 claims 23
- 238000010992 reflux Methods 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 239000002585 base Substances 0.000 claims 8
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 8
- 229910004013 NO 2 Inorganic materials 0.000 claims 7
- 238000006243 chemical reaction Methods 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000003513 alkali Substances 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003638 chemical reducing agent Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002443 hydroxylamines Chemical class 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 239000012948 isocyanate Substances 0.000 claims 3
- 150000002513 isocyanates Chemical class 0.000 claims 3
- 239000007800 oxidant agent Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Chemical group 0.000 claims 3
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 claims 2
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002841 Lewis acid Substances 0.000 claims 2
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 235000019270 ammonium chloride Nutrition 0.000 claims 2
- 239000000010 aprotic solvent Substances 0.000 claims 2
- 239000011260 aqueous acid Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 150000007517 lewis acids Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229910052763 palladium Inorganic materials 0.000 claims 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims 2
- PCTNAMGLSYHIPL-UHFFFAOYSA-N tin(4+) tetraazide Chemical compound [Sn+4].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-] PCTNAMGLSYHIPL-UHFFFAOYSA-N 0.000 claims 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 claims 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
- KKKDZZRICRFGSD-UHFFFAOYSA-N 1-benzylimidazole Chemical compound C1=CN=CN1CC1=CC=CC=C1 KKKDZZRICRFGSD-UHFFFAOYSA-N 0.000 claims 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 claims 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
- ZUSFNBJLPSRMKC-UHFFFAOYSA-N 2-[4-[(2-butyl-5-formylimidazol-1-yl)methyl]phenyl]benzoic acid Chemical compound CCCCC1=NC=C(C=O)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 ZUSFNBJLPSRMKC-UHFFFAOYSA-N 0.000 claims 1
- LQRYGEQNLPCYDT-FPYGCLRLSA-N 2-[4-[[2-[(e)-but-1-enyl]-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound CC\C=C\C1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 LQRYGEQNLPCYDT-FPYGCLRLSA-N 0.000 claims 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 150000004703 alkoxides Chemical class 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims 1
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 claims 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000012025 fluorinating agent Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 150000003949 imides Chemical class 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052987 metal hydride Inorganic materials 0.000 claims 1
- 150000004681 metal hydrides Chemical class 0.000 claims 1
- CEOCUCXOSQUXGV-UHFFFAOYSA-N methanidylphosphanium Chemical compound [PH3]=C CEOCUCXOSQUXGV-UHFFFAOYSA-N 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 150000002902 organometallic compounds Chemical class 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- 125000005592 polycycloalkyl group Polymers 0.000 claims 1
- 229910052700 potassium Chemical group 0.000 claims 1
- 239000011591 potassium Chemical group 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000007127 saponification reaction Methods 0.000 claims 1
- 229910001961 silver nitrate Inorganic materials 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000000584 angiotensin II type 2 receptor blocker Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (62)
- 일반식(I)의 화합물 및 이들 화합물의 약제학적으로 허용되는 염.상기 식에서,R1은 4-CO2H : -4-CO2R9:-OH: -SO3H, -C(CF3)2OH:-OH: -PO3H :-OH : 4-NHSO2CH3: -4-NHSO2CH3:-4-NHSO2CF3:-CONHOR12:R2는 H, Cl, Br, I, F, NC2, 탄소수 1 내지 4의 알킬, 탄소수 1 내지 4의 아실옥시, 탄소수 1 내지 4의 알콕시, CO2H, CO2R9, NHSO2CH3, NHSO2CF3, CONH OR12, SO2NH2,, 아릴 또는 푸릴이며, R3는 H, Cl, Br, I, F, 탄소수 1 내지 4의 알킬, 또는 탄소수 1 내지 4의 알콕시이고, R4는 CN, NO2또는 CO2R11이며, Ru는 H, 탄소수 1 내지 6의 알킬, 탄소수 3 내지 6의 사이클로알킬, 또는 탄소수 2 내지 4의 알케닐 또는 알키닐이고, R6는 타소수 2 내지 10의 알킬, 탄소수 3내지 10의 알케닐 또는 알키닐이거나 F 또는 CO2R14로 치환된 동일한 그룹 : 탄소수 3내지 8의 다사이클로알킬, 탄소수 4내지 10의 사이클로알킬 알킬 : 탄소수 5내지 10의 사이클로알킬알케닐 또는 사이클로알킬알키닐: F 또는 CO2R14로 임의 치환된 (CH2)SZ(CH2)mR5벤질, 또는 페닐 환 상에서 하나 또는 두개의 할로겐, 탄소수 1 내지 4의 알콕시, 탄소수 1 내지 4의 알킬, 또는 니트로에 의해 치환된 벤질이며, R7은 H,F,Cl,Br,I,NO2,CF3또는 CN이고, R8은 H,CN, 탄소수 1내지 10의 알킬, 탄소수 3내지 10의 알케닐 또는 이의 F로 치환된 동일한 그룹 : 지방족 부위의 탄소수가 2내지 6개인 페닐알케닐 :-(CH2)m-이미다졸-1-일: CO2CH3및 탄소수 1 내지 4의 알킬중에서 선택된 하나 또는 두개의 그룹으로 임의 치환된 -(CH2)m-1.2.3-트리아졸릴: -(CH2)m-테트라졸릴 :R9은이고,R10은 탄소수 1 내지 6의 알킬, 탄소수 1내지 6의 퍼플루오로알킬, 1-아다만틸, 1-나프틸, 1-(1-나프틸)에틸, 또는 (CH2)pC6H5이며, R11은 H, 탄소수 1내지 6의 알킬, 탄소수 3 내지 6의 사이클로 알킬, 페닐 또는 벤질이고, R12는 H, 메틸 또는 벤질이며,R13은 -CO2H: -CO2R9: -CH2CO2H, -CH2CO2R9:R14는 H, 탄소수 1 내지 8의 알킬 또는 퍼플루오로알킬, 탄소수 3내지 6의 사이클로알킬, 페닐, 또는 벤질이며, R15는 H, 탄소수 1내지 6의 알킬, 탄소수 3내지 6의 사이클로알킬, 페닐, 벤질, 탄소수 1내지 4의 아실, 또는 펜아실이고, R16은 H, 탄소수 1내지 6의 알킬, 탄소수 3내지 6의 사이클로알킬, (CH2)pC6H5, OR17, 또는 NR18R19이며, R17은 H, 탄소수 1내지 6의 알킬, 탄소수 3내지 6의 사이클로알킬, 페닐 또는 벤질이고, R18및 R19는 각각 독립적으로 H, 탄소수 1내지 4의 알킬, 페닐, 벤질 또는 2-메틸벤질이거나, R18및 R19가 함께는 일반식의환의 형성하며, Q는 NR20, O또는 CH2이고 : R20은 H, 탄소수 1 내지 4의 알킬, 또는 페닐이며, R21은 탄소수 1내지 6의 알킬, -NR22, O 또는CH2CO2CH3이고, R22및 R23은 각각 독립적으로 H, 탄소수 1 내지 6의 알킬 또는 벤질이거나, R22및 R23이 함께는 (CH2)u이며, 이때 u는 3내지 6이고, R24는 H, CH3또는 -C6H5이며, R26는 NR27R28, OR29, NHCONH2, NHCSNH2,또는이고, R28은 수소, 탄소수 1내지 6의 알킬, 벤질, 또는 알릴이며, R27및 R28은 각각 독립적으로 수소, 탄소수 1내지 5의 알킬, 또는 페닐이고, R29및 R30은 각각 독립적으로 탄소수 1 내지 4의 알킬이거나, R29및 R30이 함께는 -(CH2)q-이며, R31은 H, 탄소수 1내지 4의 알킬, -CH2CH=CH2, 또는 -CH2C6H4R32이고, X는 탄소-탄소 단일결합, -CO-, -O-, -S-, -NH-M-N-, -CON-, -NCO-, -OCH2-, CH20-, -SCH2-, -CH2S-, -NHC(R29)(R29), -NR23SO2-, -CH=CF-, -CF=CH-, -CH2CH2-, -CF2CH2-,,이며,Y는 O 또는 S이고, Z는 O, NR11, 또는 S이며, m는 1내지 5이고, n은 1내지 10이며, P는 0 내지 3이고, q는 2 내지 3이며, r은 0내지 2이고, s는 0내지 5이며, t는 0또는 1이고, 단, (1)R1그룹은 오르토 위치에 존재하지 않고, (2)R1이이며, X가 단일결합이고, R13이 CO3H 또는인 경우에, R13은 오르토 또는 메타 위치에 존재해야 하거나, R1및 X는 상기 정의 한 바와 같고, R13이 NHSO2CF3또는 NHSO2CH3인 경우에, R13은 오르토 위치에 존재해야 하며, (3) R1이이고 X가 단일결합을 제외한 다른 그룹일 경우에, R13은 오르토 위치에 존재해야 하며, 단, X가 NR23CO이고 R13이 NHSO2CF3또는 NHSO2CH3이면 R13은 오르토 또는 메타 위치에 존재해야 하고, (4)R1이 4-CO2H 또는 이의 염인 경우, R6는 S-알킬일 수없고, (5)R1이 4-CO2H 또는 이의 염인 경우에, 이미다졸의 4-위치상의 치환체는 CH2OH, CH2OCOCH3, 또는 CH2CO2H 일 수 없으며, (6)R1이이고, X가 -OCH2-이며, R19이 2-CO2H이고 R7이 H인 경우에, R6은 C2H5S가 아니고, (7) R1이이며, R6은 n-헥실인 경우, R7및 R8은 돌다 수소가 아니며, (8) R1이인 경우, R6은 메톡시벤질이 아니고, (9)R6그룹은또는 CH2OH가 아니다.
- 제1항에 있어서, 일반식(II)의 화합물 및 이들 화합물의 약제학적으로 허용되는 염.상기 식에서, R1은 -CH2H : -NHSO2CH3:또는이고, R6은 탄소수 3내지 10의 알킬, 탄소수 3내지 10의 알케닐, 탄소수 3내지 10의 알키닐, 탄소수 3내지의 사이클로 알킬, 또는 페닐 환 상에서 탄소수 1내지 4의 알콕시, 할로겐, 탄소수 1내지 4의 알킬, 및 니트로중에서 선택된 2개 이하의 그룹으로 치환된 벤질이며, R8은 지방족 부위의 탄소수가 2내지 4개인 페닐알케닐, -(CH2)m-이미다졸-1-일, 탄소수 1내지 4의 알킬 및 CO2CH3중에서 선택된 하나 또는 두개의 그룹으로 임의 치환된 -(CH2)m-1,2,3- 트리아졸릴, (CH2)m-테트라졸릴, -(CH2)nOR11::, -CH::: -(CH2)nNHSO2R10또는 -(CH2)mF:이고, R13은 -CO2H, -CO2R9, NHSO2CF3또는이며, R16은 H, 탄소수 1 내지 5의 알킬, OR17, 또는 NR18N19이고, X는 탄소-탄소 단일결합, -C0-,, -CH2CH2-,, -OCH2-, -CH2O-, -O-, -SCH2-, -CH2NH- 또는 -CH=CH-이다.
- 제2항에 있어서, R2가 H, 탄소수 1내지 4의 알킬, 할로겐, 또는 탄소수 1내지 4의 알콕시이고, R6은 탄소수 3내지 7의 알킬, 알케닐 또는 알키닐이며, R7은 H, Cl, Br, I 또는 CF3이고, R8은 -(CH2)mOR11, -또는 -COR16이며, R10은 CF3, 탄소수 1내지 6의 알킬, 또는 페닐이고, R11은 H, 또는 탄소수 1내지 4의 알킬이며, R13은 CO2H, CO2CH2OCOC(CH3)3, 또는이고, R14는 H 탄소수 1 내지 4의 알킬이며, R15는 H, 탄소수 1내지 4의 알킬, 또는 탄소수 1내지 4의 아실이고, R16은 H 탄소수 1내지 5의 알킬 OR17, 또는이며, 17은 1내지 5이고, X는 단일결합, -O-, -CO-, -NHCO-, 또는 -OCH2인 화합물 및 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-부틸-4-클로로-1-[(22-1H-테트라졸-5-일)비페닐-4-일)메틸]-5-(하이드록시메틸)이미다졸 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-부틸-4-클로로-1-[(22-카복시비페닐-4-일)메틸]-5-(하이드록시메틸)이미다졸 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-부틸-4-클로로-1[(22-카복시비페닐-4-일)메틸]-5-[(메톡시카보닐)아미노메틸]이미다졸 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-부틸-4-클로로-1-[(22-카복시비페닐-4-일)메틸]-5-[(프로폭시카보닐)아미노메틸)이미다졸 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-부틸-4-클로로-1-[(22-카복시비페닐-4-일)메틸]이미다졸-5-카복스알데하이드 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-부틸-1-[(2'-카복시비페닐-4-일)메틸]이미다졸-5-카복스알데하이드 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-(1E-부테닐)-4-클로로-1-[(2'-카복시비페닐-4-일)메틸]-5-(하이드록시메틸)이미다졸 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-(1E-부테닐)-4-클로로-1-[(22-카복시비페닐-4-일)메틸]이미다졸-5-카복스알데하이드 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-프로필-4-클로로-1-[22(1H-테트라졸-5-일)비페닐-4-일)메틸]-5-(하이드록시메틸)이미다졸 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-프로필-4-클로로-1-[22-(1H-테트라졸-5-일)비페닐-4-일)메틸]이미다졸-5-카복스알데하이드 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-부틸-4-클로로-1-[22-(1H-테트라졸-5-일)비페닐-4-일)메틸)이미다졸-5-카복스알데하이드 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-(1E-부테닐)-4-클로로-1-[(22-1H-테트라졸-5-일)비페닐-4-일)메틸]-5-(하이드록시메틸)이미다졸 또는 이의 약제학적으로 허용되는 염.
- 제3항에 있어서, 2-(1E-부테닐)-4-클로로-1-[(22-1H-테트라졸-5-일)비페닐-4-일)메틸]이미다졸-5-카복스알데하이드 또는 이의 약제학적으로 허용되는 염.
- 약제학적으로 적합한 담체 및 제1항 내지 16항중의 어느 한 항에 따른 화합물을 함유하는 약제학적 조성물.
- 제1항 내지 16항중의 어느 한 항에 따른 화합물을 동물의 혈압을 강하시키기에 효과적인 양으로 온혈동물에 투여하여 온혈동물의 고혈압을 치료하는 방법.
- 심장에 미치는 혈압을 정상화하여 울혈증을 완화시키기에 효과적인 양의 제1항 내지 16항중의 어느 한항에 따른 화합물을 온혈동물에 투여하여 온혈동물의 울혈성 심부전증을 치료하는 방법.
- 일반식(1)의 이미다졸 유도체를 염기의 존재하에 약 20℃내지 용매의 환류온도에서 약 1내지 약 10시간동안 용매중의 일반식(2)의 벤질 유도체와 접촉시켜 일반식(3)의 벤질이미다졸을 생성시킨 다음, 필요한 경우 R그룹의 중간형태 또는 보호된 형태를 제1항에서 정의한 R그룹으로 전환시킴을 특징으로 하여, r이 1인 제1항의 화합물을 제조하는 방법.상기식에서, R1, R2, R3, R6, R7및 R8은 각각 반응 조건하에서 안정하며, 제1항에서 정의한 그룹이거나 그러한 그룹으로 전환시킬 수 있는 그의 중간 형태 또는 보호된 형태이고, X'은 할로겐, p-톨루엔설포닐옥시 또는 메틸설포닐옥시이다.
- 제20항에 있어서, 화합물(1)과 화합물(2)를 금속 하이드라이드, MH, 금속 알콕사이, MOR, 탄산나트륨, 탄산칼륨, 트리에틸아민 및 피리딘으로 이루어진 그룹중에서 선택된 염기의 존재하에 양극성 비양성자성 용매 또는 염기가 MOR인 경우에는 알콜(ROH)중에서 접촉시키며 이때, M은 리튬, 나트륨 또는 칼륨이고, R은 메틸, 에틸 또는 t-부틸인 방법.
- 제20항에 있어서, R1이이고 : X가 탄소-탄소 단일결합, -CO-, -O-, -S-, 또는 -NH-이며; R2및 R3가 각각 독립적으로 H, Cl, Br, I, CO2R14, F, NO2, 탄소수 1내지 4의 알킬, 탄소수 1내지 4의 알콕시, 아릴 또는 푸릴이고; R8은 탄소수 1내지 10의 알킬 또는 탄소수 3내지 10의 알케닐, 또는 F로 치환된 동일한 그룹, 지방족 부위의 탄소수가 2내지 6개인 페닐알케닐, -(CH2)nOR11, -(CH2)nSR15, 또는 -(CH2)nCN이며: R13은 CO2R14, CN, NO2, 트리알킨테트라졸, 또는 트리틸테트라졸이고 : R6, R7, R11, R14및 R15는 제20항에서 정의한 바와 같은 방법.
- 제22항에 있어서, R13이 -CO2R14이고 일반식(3)의 생성물을 약20℃내지 용매의 환류온도에서 약 1내지 24시간동안 알콜성 수성용매중의 알카리와 접촉시키거나 CF3CO2H와 접촉시킨후 혼합물의 PH를 3내지 7의 범위로 조정하여 생성물을 R13이 -CO2H인 상응하는 생성물로 전환시키는 방법.
- 제23항에 있어서, 일반식(1)에서 R2, R3, 및 R13중 적어도 한 그룹이 -CO2R14이고 이를 -CO2H로 전환시키는 방법.
- 제23항에 있어서, R14가 t-부틸이고 반응을 CF3CO2H 중에서 수행하는 방법.
- 제22항에 있어서, R13이 -CN이고, 일반식(3)의 생성물을, (i)용매의 환류온도에서 약 2내지 96시간동안 강산과 접촉시키거나, (ii)약 20℃내지 용매의 환류온도에서 약2내지 96시간동안 알콜 용매중의 강 알카리와 접촉시킨 후 혼합물의 PH를 약 3내지 7로 조정하거나, (iii)황산과 접촉시킨 다음 산 또는 알카리와 접촉시킴으로써, 생성물을 R13이 -CO2H인 상응하는 화합물로 전환시키는 방법.
- 제26항에 있어서, R2, R3및 R13중적어도 한 그룹이 -CO2R14이고 이를 -CO2H로 전환시키는 방법.
- 제26항에 있어서, R13을 -CO2H로 전환시킬 경우 R8이 -(CH2)nCN이고 이를 -(CH2)nCH2H로 전환시키거나, R8이 -(CH2)nOR11이고 이를 (CH2)nOH로 전환시키는 방법.
- 제22항에 있어서, R13이 -CN이고 일반식 (3)의 생성물을 약 30℃내지 용매의 환류온도에서 약 1시간 내지 10일동안 극성 비양성자성 용매중의 나트륨아지드 및 염화암모늄 등몰량의 혼합물과 접촉시켜 생성물을 R13이 5-테트라졸릴인 상응하는 화합물로 전환시키는 방법.
- 제29항에 있어서, R13을 5-테트라졸릴로 전환시킬 경우에 R8이 -(CH2)CN이고 이를 -(CH2)m-테트라졸릴로 전환시키는 방법.
- 제22항에 있어서, R13이 -CN이고 일반식 (3)의 생성물을 트리알킬틴 아지드 또는 트리아릴틴 아지드와 반응시킨 다음 산성 또 염기성 가수분해에 의해 생성물을 R13이 5-테트라졸릴인 상응 화합물로 전환시키는 방법.
- 제31항에 있어서, R13을 5-테트라졸릴로 전환시킬 경우에 R8이 -(CH2)nCN 이며 이를 -(CH2)n-테트라졸릴로 전환시키는 방법.
- 제22항에 있어서, R13이 -NO2이고, 일반식 (3)의 생성물을 환원제와 접촉시켜 R13이 NH2인 일반식(3)의 제2중간체를 생성한 다음 이를 용매중에서 설폰산의 무수물 (CH3SO2)2O 또는 (CF3SO2)2O 또는 설폰산의 염화물 CH3SO2Cl 또는 F3SO2Cl과 접촉시켜 R13이 -NHSO2CH3또는 -NHSO2CF3인 화합물을 생성하는 방법.
- 제33항에 있어서, R23, 및 R13중 적어도 한 그룹은 -NO2이고 이를 -NHSO2CH3또는 -NHSO2CF3로 전환시키는 방법.
- 제23항 또는 26항에 있어서, R16이 CO2H인 일반식(3)의 화합물을, (a)약 20℃내지 용매의 환류온도에서 약5분 내지 약 2시간동안 과량의 티오닐클로라이드 또는 다른 용매중에서 약 1내지 4당량의 티오닐 클로라이드와 접촉시켜 R13이 COCl인 일반식(3)의 중간체를 형성한 후 이를 약 25내지 80℃의 온도에서 약 12내지 18시간동안 과량의 하이드록실아민 유도체 H2NOR12또는 다른 용매중에서 약 2내지 10당량의 하이드록실 아민유도체 H2NOR12와 접촉시키거나, (b) 약 0 내지 30℃의 온도에서 약 1내지 24시간동안 용매중에서 하이드록실아민 유도체 N2NOR12, 디사이클로헥실카보디아미드 및 1-하이드록시벤조트리아졸과 접촉시켜 R13이 CONHOR12인 화합물을 수득하는 방법.
- 제20항에 있어서, R1이,또는이고 : X가 탄소-탄소 단일결합, -CO-, -O-, -S-, 또는 -NH-이며 : R2, R3, R6및 R7이 제20항에서 정의한 바와 같고 : R3이 (CH2)nOR11, (CH2)nOCOR14, (CH2)nCH(OH)R16, (CH2)nCOR10, (CO2)nCl, (CH2)nCN, 또는 CHO인 방법.
- 제36항에 있어서, R8이 (CH2)nOH이고 일반식(3)의 생성물을 강산 또는 루이스산의 존재하에 무수상태의 알콜 R11OH와 접촉시킨 후 중간체 3과 동시에 형성되거나 중간체 3에 존재하는 모든 CO2R14그룹을 비누화하여 R8이 (CH2)nOR11이고 R11이 H가 아닌 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nOR11이고 R11이 H가 아니며 일반식(3)의 생성물을 약 25℃내지 용매의 환류온도에서 약 0.5내지 24시간동안 산수용액매질과 접촉시켜 R8이 (CH2)nOH인 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)OH이고 일반식(3)의 생성물을, (a)약0℃내지 용매의 환류온도에서 약 0.5내지 24시간동안 염기의 존재하에, 용매중에서 카복실산 무수물 (R14CO)2O 또는 염화물 R14COCl과 접촉시키거나, (b)약0℃ 내지 100℃에서 약 0.5내지 24시간동안 강산 또는 루이스산의 존재하에 무수조건하에 카복실산 R14CO2H와 접촉시켜, R8이 (CH2)nOCOR14인 상응하는 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nOH이고 일반식(3)의 생성물을 수성산 또는 알카리와 접촉시켜 R8이 (CH2)nOH인 상응하는 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nOH이고 일반식(3)의 생성불을 약 25 내지 45℃의 온도에서 약 1내지 200시간동안 산화제와 접촉시켜 R8이 (CH2)n-1COR16이고 R16이 H인 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CO2)nCOR16이고 R16이 H이며 일반식(3)의 생성물을 용매중 약 -78℃내지 100℃의 온도에서 약 0.5내지 24시간동안 P가 MgBr 또는 Li인 유기금속 화합물 R16p와 접촉시켜 R8이 (CH2)nCH(CH)R16이고 R16이 H가 아닌 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nCH(OH)R16이고 R16은 H가 아니며 일반식(3)의 생성물을 용매중에서 산화제와 접촉시켜 R8이 (CH2)nCOR16이고 R16이 H가 아닌 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nCOR16이고 R16은 H가 아니며 일반식(3)의 화합물을 용매중에서 산화제와 접촉시켜 R8이 (CH2)nCOR16이고 R16이 OH인 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nCOR16이고 R16이 OH이며 일반식(3)의 화합물을 약 0℃내지 용매의 환류온도에서 약 5분 내지 약 24시간동안 과량의 티오닐클로라이드와 반응시키거나 다른 용매중의 티오닐 클로라이드와 반응시켜 R3이 (CH2)nCOCl인 상응하는 일반식(3)의 화합물을 수득한 후 이 화합물을 약 0℃내지 용매의 환류온도에서 약 5분 내지 약 24시간동안 아민 NHR18R15(량과 반응시키거나 용매중의 아민 NHR18R19와 반응시켜 R8이 (CH2)nCONR18R19인 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nOR11이고 R11이 H이며 일반식(3)의 생성물을 약 20℃내지 용매의 환류온도에서 약 0.5내지 24시간동안 과량의 티오닐클로아이드와 접촉시키거나 용매중의 티오닐 클로라이드와 접촉시켜 R8이 (CH2)nCl인 일반식(3)의 중간체 화합물을 수득하는 방법.
- 제46항에 있어서, R8이 (CH2)mCl인 일반식(3)의 화합물을 용매중, 약 55℃내지 용매의 환류온도에서 약 1내지 24시간동안 염기의 존재하에 이미다졸, 1,2,3-트리아졸, 1,2,4-테트라졸 또는 프탈이미드와 접촉시켜 R8이 (CH2)m-이미다졸, (CH2)m-트리아졸, (CH2)]m-테트라졸 또는 (CH2)m-프탈이미드인 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제46항에 있어서, R8이 (CH2)nCl인 일반식(3)의 화합물을 약 25내지 100℃에서 약 1내지 24시간동안 용매중에서 머캅탄 R15SH의 나트륨 또는 칼륨염과 접촉시켜 R8이 (CH2nSR15인 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nCl인 일반식(3)의 화합물을 약 20내지 100℃에서 약1내지 24시간동안 용매중에서 알카리 금속 시아나이드와 접촉시켜 R8이 (CH2)nCN인 일반식(3)의 화합물을 수득하고 이 화합물을 가수분해시켜 R8이 (CH2)nCOR16이고 R16이 OH인 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)n-1Cl인 일반식(3)의 화합물을 약 20 내지 100℃에서 약 0.5 내지 24시간동안 용매중에서 디알킬 말로네이트의 나트륨 또는 칼륨염과 접촉시켜 R8이 (CH2)nCH(CO2알킬)2인 일반식(3)의 화합물을 수득한 후 이화합물을 약 25℃ 내지 용매의 환류온도에서 수성 알키리노 비누화한 다음 무기산으로 산성화하여 R8이 (CH2)nCH(CO2H)2인 일반식(3)의 화합물을 수득하고, 이어서 이 화합물을 약 120℃로 가열하거나 희무기산 중에서 환류온도로 가열하여 R8이 (CH2)nCOR16이고 R16이 OH인 일반식(3)의 생성물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nCN이고 일반식(3)의 화합물을 약 30℃ 내지 용매의 환류온도에서 약 1시간 내지 약 10일동안 용매중에서 나트륨 아지드 및 염화암모늄과 접촉시켜 R8이 (CH2)n-테트라졸인 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 -CHO이고 일반식(3)의 화합물을 약 25℃ 내지 용매의 한류온도에서 약 1 내지 24시간 동안 용매중에서 메틸렌포스포란 (C6H5)3P= CH(CH2)SCHR14OR15또는 (C6H5)3P=CH2)5COR16과 접촉시켜 R8이 -CH=CH(CH2)SCHR14OR15또는 -CH=CH(CH2)SCOR16(단, R15는 H가 아니고 R16은 OH가 아니다)인 일반식(3)의 화합물을 수득한 후, 임의로는 R8이 -CH=CH(CH2)SCOR16인 일반식(3)의 화합물을 약 0°내지 25℃의 온도에서 약 0.5 내지 24시간 동안 용매중에서 환원제와 접촉시켜 R8이 -CH=CH(CH2)SCHR14OH인 일반식(3)의 생성물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)mOH이고 일반식(3)의 화합물을 -30℃ 내지 25℃의 온도에서 약 0.5 내지 24시간 동안 용매중에서 불소화제와 접촉시켜 R8이 (CH2)mF인 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)mCl인 일반식(3)의 화합물을 -25℃ 내지 80℃의 온도에서 약 1 내지 24시간 동안 양극성 비양자성 용매중에서 질산은과 접촉시켜 R8이 (CH2)mONO2인 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nOH이고 일반식(3)의 화합물을 약 25℃ 내지 용매의 환류온도에서 약 5분 내지 약 24시간 동안 용매중에서 일반식 R16NCO의 이소시아네이트와 접촉시켜 R8이 (CH2)nOCONHR10인 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nCl인 화합물을 약 25℃ 내지 용매의 환류온도에서 약 5분 내지 약 24시간 동안 용매중에서 일반식 R10NCO의 이소시아네이트와 접촉시켜 R8이 (CH2)nOCONHR10인 일반식(3)의 화합물을 수득하는 방법.
- 제36항에 있어서, R8이 (CH2)nCl이고 일반식(3)의 화합물을 약 25 내지 80℃의 온도에서 약 1 내지 24시간동안 비양자성 용매중에서 알카리 금속 아지드와 접촉시켜 R8이 (CH2)nN3인 일반식(3)의 화합물을 수득하고 이 화합물을 환원제와 접촉시켜 R8이 (CH2)nNH2인 일반식(3)의 중간체를 수득하는 방법.
- 제56항 또는 57항에 있어서, R8이 (CH2)nNHR11또는 (CH2)nNH3이고 일반식(3)의 화합물을 약 0℃ 내지 용매의 환류온도에서 약 5분 내지 24시간동안 염기의 존재하에 용매중에서 일반식 R10OCOCL의 클로로포르메이트, 또는 일반식 R10SO2Cl 또는 (R10SO2)O의 설포닐 유도체와 접촉시켜 R8이 -(CH2)nNR11CO2R10또는 -(CH2)nNR11SO2R10인 일반식(3)의 화합물을 수득하는 방법.
- 제56항 또는 57항에 있어서, R8이 -(CH2)nNHR11또는 (CH2)nNH2인 일반식(3)의 화합물을 약 25℃ 내지 용매의 환류온도에서 약 5분 내지 약 24시간 동안 용매중에서 이소시아네이트 또는 이소티오시아네이트 R10NCY와 접촉시켜 R8이 -(CH2)nNR11CYNHR10인 일반식(3)의 화합물을 수득하는 방법.
- 제20항에 있어서, R1이 NH2인 일반식(3)의 화합물을 철 및 아세트산, 염화제일주석 또는 수소 및 팔라듐으로 환원시켜 R1이 NO2인 일반식(3)의 화합물을 수득하고 이 화합물을 용매중에서 프탈산 무수물 또는 치환된 프탈산 무수물과 같은 적합한 산 무수물과 반응시키거나, 수성 알카리 또는 염기의 존재하에 치환된 안트라닐린 클로라이드와 같은 적합한 산 클로라이드와 반응시키거나, 디사이클로헥실카보니이미드의 존재하에 용매중에서 적절히 치환된 프탈산 또는 안트라닐신과 반응시켜, R1이,또는이고 X가 NHCO인 일반식(3)의 화합물을 수득하는 방법.
- 제20항에 있어서, R1이 OCH2C6H5이고 R2및 R3는 H이고 R6, R7및 R8은 제20항에서 정의한 바와 같고 : R1이 OCH2C6H5인 일반식(3)의 생성물을 환류온도에서 약 0.2 내지 1시간 동안 트리플루오로아세트산과 접촉시키거나 수소 및 팔라듐과 접촉시켜, R1이 OH인 상응하는 일반식(3)의 화합물을 수득한 후 이 화합물을 약 25℃에서 염기 및 일반식 또는의 적합한 벤질 할라이드와 접촉시켜 R1이,또는이고 X가 -OCH2-인 상응하는 일반식(3)의 화합물을 수득하는 방법.
- 제20항에 있어서, R8이 -CHO이고 일반식(2)의 벤질유도체를 R8이 연결된 이미다졸 환의 탄소원자에 인접한 질소원자에 선택적으로 일반식(1)의 이미다졸 유도체에 결합시키는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019900002283A KR900005045B1 (ko) | 1986-07-11 | 1990-02-23 | 앤지오텐신 ii수용체 차단 이미다졸 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88492086A | 1986-07-11 | 1986-07-11 | |
US884,920 | 1986-07-11 | ||
US884920 | 1986-07-11 | ||
US5034187A | 1987-05-22 | 1987-05-22 | |
US050,341 | 1987-05-22 | ||
US50341 | 1987-05-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900002283A Division KR900005045B1 (ko) | 1986-07-11 | 1990-02-23 | 앤지오텐신 ii수용체 차단 이미다졸 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880001609A true KR880001609A (ko) | 1988-04-25 |
KR900005020B1 KR900005020B1 (ko) | 1990-07-18 |
Family
ID=26728162
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870007464A KR900005020B1 (ko) | 1986-07-11 | 1987-07-11 | 앤지오텐신 ii 수용체 차단 이미다졸 |
KR1019900002283A KR900005045B1 (ko) | 1986-07-11 | 1990-02-23 | 앤지오텐신 ii수용체 차단 이미다졸 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900002283A KR900005045B1 (ko) | 1986-07-11 | 1990-02-23 | 앤지오텐신 ii수용체 차단 이미다졸 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0253310B1 (ko) |
KR (2) | KR900005020B1 (ko) |
AT (1) | ATE113276T1 (ko) |
AU (1) | AU599396B2 (ko) |
CA (1) | CA1334092C (ko) |
CY (1) | CY1855A (ko) |
DE (2) | DE19675001I2 (ko) |
DK (1) | DK174700B1 (ko) |
ES (1) | ES2063734T4 (ko) |
FI (1) | FI96025C (ko) |
HK (1) | HK55495A (ko) |
HU (2) | HU218460B (ko) |
IE (1) | IE69984B1 (ko) |
IL (1) | IL83153A (ko) |
LU (1) | LU88662I2 (ko) |
LV (1) | LV5486A3 (ko) |
NL (1) | NL950009I2 (ko) |
NO (2) | NO176049C (ko) |
PT (1) | PT85312B (ko) |
SU (1) | SU1694062A3 (ko) |
Families Citing this family (283)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY100938A (en) * | 1986-06-06 | 1991-05-31 | Ciba Geigy Ag | Arylkylimidazole derivatives. |
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US4851423A (en) * | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
IL86134A (en) * | 1987-05-02 | 1993-06-10 | Basf Ag | N-substituted azoles, their manufacture and their use as pesticides and compositions containing them |
US4820843A (en) * | 1987-05-22 | 1989-04-11 | E. I. Du Pont De Nemours And Company | Tetrazole intermediates to antihypertensive compounds |
US5081127A (en) * | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
US5210079A (en) * | 1988-01-07 | 1993-05-11 | E. I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists |
US5189048A (en) * | 1988-01-07 | 1993-02-23 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3 triazole angiotensin II antagonists |
US5315013A (en) * | 1988-01-07 | 1994-05-24 | E. I. Du Pont De Nemours And Company | Substituted pyrazole angiotensin II antagonists |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
US5354867A (en) * | 1988-12-06 | 1994-10-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
US4916129A (en) * | 1989-01-19 | 1990-04-10 | E. I. Du Pont De Nemours And Company | Combination β-blocking/angiotensin II blocking antihypertensives |
DE3928177A1 (de) * | 1989-04-08 | 1991-02-28 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
CA2016710A1 (en) * | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
GB8911854D0 (en) * | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
US5332744A (en) * | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
IL94390A (en) * | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
US5157026A (en) * | 1989-05-30 | 1992-10-20 | Merck & Co., Inc. | Oxo-purines as angiotensin II antagonists |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
CA2018443A1 (en) * | 1989-06-14 | 1990-12-14 | Joseph A. Finkelstein | Imidazolyl-alkenoic acids |
US5418250A (en) * | 1989-06-14 | 1995-05-23 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
EP0955294B1 (en) * | 1989-06-14 | 2003-09-24 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acid |
US5312828A (en) * | 1989-06-14 | 1994-05-17 | Finkelstein Joseph A | Substituted imidazoles having angiotensin II receptor blocking activity |
KR0163595B1 (ko) * | 1989-06-30 | 1998-12-01 | 미리암디, 메코너헤이 | 치환된 이미다졸 |
KR950009860B1 (ko) | 1989-06-30 | 1995-08-29 | 이. 아이. 듀퐁 드 네모아 앤드 캄파니 | 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물 |
US5240928A (en) * | 1989-07-03 | 1993-08-31 | Merck & Co., Inc. | Substituted quinazolinones as angiotensin II antagonists |
CA2020073A1 (en) * | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
EP0407342A3 (en) * | 1989-07-06 | 1991-07-10 | Ciba-Geigy Ag | Pyrimidine derivatives |
EP0409332A3 (en) * | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
DE69013607T2 (de) * | 1989-08-02 | 1995-03-02 | Takeda Chemical Industries Ltd | Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung. |
YU155290A (sh) * | 1989-08-11 | 1993-05-28 | Imperial Chemical Industries Plc. | Dusikove spojine |
US5100897A (en) * | 1989-08-28 | 1992-03-31 | Merck & Co., Inc. | Substituted pyrimidinones as angiotensin ii antagonists |
IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
US5298518A (en) * | 1989-09-29 | 1994-03-29 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
EP0424317A3 (en) * | 1989-10-19 | 1991-09-25 | Ciba-Geigy Ag | Pyrimidines |
IL95975A (en) * | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
US5250554A (en) * | 1989-10-24 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives useful as angiotensin II inhibitors |
US5177096A (en) * | 1989-10-25 | 1993-01-05 | Smithkline Beecham Corporation | Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof |
CA2027937A1 (en) * | 1989-10-25 | 1991-04-26 | Richard M. Keenan | Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles |
IL96019A0 (en) * | 1989-10-31 | 1991-07-18 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
CA2028925A1 (en) * | 1989-11-06 | 1991-05-07 | Gerald R. Girard | Substituted n-(imidazolyl)alkyl alanine derivatives |
US5248689A (en) * | 1989-11-06 | 1993-09-28 | Smithkline Beecham Corporation | Substituted N-(imidazolyl)alkyl alanine derivatives |
PT95899A (pt) * | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
IE903911A1 (en) * | 1989-11-20 | 1991-05-22 | Ici Plc | Diazine derivatives |
US5073566A (en) * | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
US5104891A (en) * | 1989-12-11 | 1992-04-14 | G. D. Searle & Co. | Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension |
EP0434038A1 (en) * | 1989-12-22 | 1991-06-26 | Takeda Chemical Industries, Ltd. | Fused imidazole derivatives, their production and use |
ZA9010460B (en) * | 1989-12-29 | 1992-11-25 | Univ Technologies Int | Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin |
US5234917A (en) * | 1989-12-29 | 1993-08-10 | Finkelstein Joseph A | Substituted 5-(alkyl)carboxamide imidazoles |
US5449682A (en) * | 1990-02-13 | 1995-09-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted benzyl element |
DE69129998T2 (de) * | 1990-02-15 | 1998-12-24 | Takeda Chemical Industries Ltd | Pyrimidindionderivate, deren Herstellung und Verwendung |
DE19675036I2 (de) * | 1990-02-19 | 2004-10-21 | Novartis Ag | Acylverbindungen. |
MY106533A (en) * | 1990-02-20 | 1995-06-30 | Sumitomo Chemical Co | A 4-tert.-butyl imidazole derivative and its production and use. |
US5284661A (en) * | 1990-02-22 | 1994-02-08 | Takeda Chemical Industries, Ltd. | Fused thiophene derivatives, their production and use |
CA2037630C (en) * | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
NZ237476A (en) * | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
FR2665702B1 (fr) * | 1990-08-08 | 1994-02-25 | Sanofi | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
FR2659967B1 (fr) * | 1990-03-20 | 1992-07-24 | Sanofi Sa | Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
US5166206A (en) * | 1990-03-30 | 1992-11-24 | Merck & Co., Inc. | Substituted pyrimidines, pyrimidinones and pyridopyrimidines |
DE4010797A1 (de) * | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
GB2244054B (en) * | 1990-04-19 | 1994-04-06 | Ici Plc | Pyridine derivatives |
US5198439A (en) * | 1990-04-19 | 1993-03-30 | Imperial Chemical Industries Plc | Angiotension II antagonizing pyridine derivatives |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US6004989A (en) * | 1990-04-27 | 1999-12-21 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
ZA912983B (en) | 1990-04-27 | 1992-01-29 | Takeda Chemical Industries Ltd | Benzimidazole derivatives,their production and use |
US5098920A (en) * | 1990-05-04 | 1992-03-24 | G. D. Searle & Co. | 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders |
US5821232A (en) * | 1990-05-11 | 1998-10-13 | Pfizer Inc. | Synergistic therapeutic compositions and methods |
HU227346B1 (en) | 1990-05-11 | 2011-04-28 | Pfizer | Process for producing synergetic pharmaceutical composition |
US5045540A (en) * | 1990-05-25 | 1991-09-03 | Warner-Lambert Co. | Amino acid derivatives with angiotensin II antagonist properties |
FR2674523A1 (fr) * | 1991-03-28 | 1992-10-02 | Roussel Uclaf | Nouveaux derives de benzimidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
DK0461039T3 (da) * | 1990-06-08 | 1999-06-14 | Hoechst Marion Roussel Inc | Nye benzimidazolafledte forbindelser, fremgangsmåde til deres fremstilling, de opnåede mellemprodukter, deres anvendelse so |
FR2663028B1 (fr) * | 1990-06-08 | 1994-10-14 | Roussel Uclaf | Nouveaux derives de benzimidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
AU653524B2 (en) | 1990-06-08 | 1994-10-06 | Roussel-Uclaf | New imidazole derivatives, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them |
FR2670489B1 (fr) * | 1990-12-18 | 1994-10-14 | Roussel Uclaf | Nouveaux derives de benzimidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
AU7983691A (en) * | 1990-06-15 | 1992-01-07 | G.D. Searle & Co. | 1h-substituted-imidazo{4,5-d}pyridazine compounds for treatment of cardiovascular disorders |
NZ238688A (en) * | 1990-06-28 | 1992-05-26 | Smithkline Beecham Corp | Substituted histidines: pharmaceutical compositions, preparation and uses thereof |
CA2036148A1 (en) * | 1990-06-29 | 1991-12-30 | Hiroki Tomioka | A 1-phenylimidazole derivative and its production and use |
FR2675503B1 (fr) * | 1991-04-19 | 1994-02-18 | Roussel Uclaf | Nouveaux derives soufres de l'imidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
FR2664271B1 (fr) * | 1990-07-05 | 1994-02-18 | Roussel Uclaf | Nouveaux derives soufres de l'imidazole, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
IL98319A (en) * | 1990-07-05 | 1997-04-15 | Roussel Uclaf | Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them |
CA2044806A1 (en) * | 1990-07-18 | 1992-01-19 | Roland Jaunin | Purine derivatives |
DE4023215A1 (de) * | 1990-07-21 | 1992-01-23 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung |
NZ239161A (en) * | 1990-07-31 | 1994-01-26 | Smithkline Beecham Corp | Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments, |
GB9017480D0 (en) * | 1990-08-09 | 1990-09-26 | Ici Plc | Chemical process |
GB9017482D0 (en) * | 1990-08-09 | 1990-09-26 | Ici Plc | Manufacturing process |
WO1992002257A2 (en) * | 1990-08-10 | 1992-02-20 | G.D. Searle & Co. | Renal-selective angiotensin ii antagonists for treatment of hypertension |
US5089626A (en) * | 1990-08-23 | 1992-02-18 | Merck & Co., Inc. | Process for preparing an angiotensin II antagonist |
US5217985A (en) * | 1990-08-28 | 1993-06-08 | G. D. Searle & Co. | Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension |
US5140036A (en) * | 1990-09-19 | 1992-08-18 | G. D. Searle & Co. | 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
US5229406A (en) * | 1990-09-19 | 1993-07-20 | G. D. Searle & Co. | 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
US5091390A (en) * | 1990-09-20 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs |
EP0481614A1 (en) * | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
US5126342A (en) * | 1990-10-01 | 1992-06-30 | Merck & Co., Inc. | Imidazole angiotensin ii antagonists incorporating acidic functional groups |
AU9024591A (en) * | 1990-10-25 | 1992-05-26 | G.D. Searle & Co. | Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders |
AU636066B2 (en) * | 1990-10-30 | 1993-04-08 | Takeda Chemical Industries Ltd. | Thienoimidazole derivatives, their production and use |
US5087634A (en) * | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
US5238952A (en) * | 1990-10-31 | 1993-08-24 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
GB9025123D0 (en) * | 1990-11-19 | 1991-01-02 | Ici Plc | Nitrogen compounds |
EP0563238B1 (en) * | 1990-12-14 | 2002-05-22 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
US5175180A (en) * | 1990-12-20 | 1992-12-29 | G. D. Searle & Co. | N-substituted n-(alpha-triazolyl-toluyl)pyrrole compounds and use for treatment of circulatory disorders |
CA2058198A1 (en) * | 1991-01-04 | 1992-07-05 | Adalbert Wagner | Azole derivatives, process for their preparation, and their use |
IE914572A1 (en) * | 1991-01-17 | 1992-07-29 | Zeneca Ltd | Chemical process |
IE914573A1 (en) * | 1991-01-17 | 1992-07-29 | Ici Plc | Boron compounds |
AT395853B (de) * | 1991-01-31 | 1993-03-25 | Chem Pharm Forsch Gmbh | Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung |
GB9102803D0 (en) * | 1991-02-11 | 1991-03-27 | Ici Plc | Pyridine compounds |
IE920175A1 (en) * | 1991-02-11 | 1992-08-12 | Zeneca Ltd | Nitrogen heterocycles |
FR2672892B1 (fr) * | 1991-02-20 | 1994-01-14 | Synthelabo | Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique. |
US5472967A (en) * | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
IS1756B (is) | 1991-02-21 | 2000-12-28 | Sankyo Company Limited | Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða |
US6008368A (en) * | 1993-04-28 | 1999-12-28 | G. D. Searle & Co. | Pharmaceutical compositions for treatment of circulatory disorders using N-substituted (α-imidazolyl-toluyl) pyrrole aniotensin II antagonists |
US5187271A (en) * | 1991-02-28 | 1993-02-16 | G. D. Searle & Co. | N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders |
US5385894A (en) * | 1991-03-06 | 1995-01-31 | Merck & Co., Inc. | Disubstituted 6-aminoquinazolinones |
US5202328A (en) * | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
EP0502575A1 (en) * | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
US5191086A (en) * | 1991-03-19 | 1993-03-02 | E.R. Squibb & Sons, Inc. | Imidazole and benzimidazole derivatives |
EP0505098A1 (en) * | 1991-03-19 | 1992-09-23 | Merck & Co. Inc. | Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists |
US5236928A (en) * | 1991-03-19 | 1993-08-17 | Merck & Co., Inc. | Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists |
US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
US5196537A (en) * | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
US5187179A (en) * | 1991-03-22 | 1993-02-16 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole |
US5128327A (en) * | 1991-03-25 | 1992-07-07 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle |
US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5164403A (en) * | 1991-04-05 | 1992-11-17 | G. D. Searle & Co. | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders |
US5155117A (en) * | 1991-04-12 | 1992-10-13 | G. D. Searle & Co. | 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders |
TW274551B (ko) * | 1991-04-16 | 1996-04-21 | Takeda Pharm Industry Co Ltd | |
US5190942A (en) * | 1991-04-22 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives |
CZ227093A3 (en) * | 1991-04-29 | 1994-03-16 | Merck & Co Inc | Mixture suitable for the preparation of tablets by direct moulding |
US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
US5506361A (en) * | 1991-05-08 | 1996-04-09 | Theupjohn Company | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same |
US5223501A (en) * | 1991-05-10 | 1993-06-29 | Merck & Co., Inc. | Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists |
GB9110625D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
GB9110636D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
US5332820A (en) * | 1991-05-20 | 1994-07-26 | E. I. Du Pont De Nemours And Company | Dibenzobicyclo(2.2.2) octane angiotensin II antagonists |
US5175164A (en) * | 1991-06-05 | 1992-12-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted indole or dihydroindole |
FR2677984B1 (fr) * | 1991-06-21 | 1994-02-25 | Elf Sanofi | Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
US5210211A (en) * | 1991-06-21 | 1993-05-11 | Warner-Lambert Company | 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity |
IL102183A (en) * | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
US5177097A (en) * | 1991-07-24 | 1993-01-05 | E. R. Squibb & Sons, Inc. | Acyl amidine and acyl, guanidine substituted biphenyl derivatives |
AU644540B2 (en) * | 1991-09-10 | 1993-12-09 | Tanabe Seiyaku Co., Ltd. | Imidazopyridine derivatives and process for preparation thereof |
ATE146474T1 (de) * | 1991-09-10 | 1997-01-15 | Tanabe Seiyaku Co | Imidazoindolizinderivate mit angiotensin-ii hemmwirkung |
ES2162792T3 (es) * | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d. |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
AT398202B (de) * | 1991-10-04 | 1994-10-25 | Chem Pharm Forsch Gmbh | Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung |
US5187159A (en) * | 1991-10-07 | 1993-02-16 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole |
US5149699A (en) * | 1991-10-24 | 1992-09-22 | American Home Products Corporation | Substituted pyridopyrimidines useful as antgiotensin II antagonists |
US5256654A (en) * | 1991-10-24 | 1993-10-26 | American Home Products Corporation | Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines useful as angiotensin II antagonists |
US5484937A (en) * | 1992-08-04 | 1996-01-16 | G.D. Searle & Co. | N-substituted N-(α-triazolyl-toluyl)pyrrole compounds for treatment of circulatory disorders |
US5252753A (en) * | 1991-11-01 | 1993-10-12 | Ortho Pharmaceutical Corporation | Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof |
US5322950A (en) * | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
US5389661A (en) * | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
US5234923A (en) * | 1991-12-16 | 1993-08-10 | E. R. Squibb & Sons, Inc. | Substitute indole and benzimidazole derivatives |
US5212177A (en) * | 1991-12-16 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Indole and benzimidazole-substituted dihydropyrimidine derivatives |
US5350752A (en) * | 1991-12-16 | 1994-09-27 | E. R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
US5308853A (en) * | 1991-12-20 | 1994-05-03 | Warner-Lambert Company | Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties |
EP0550313A1 (fr) * | 1991-12-30 | 1993-07-07 | Synthelabo | Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse |
FR2685697B1 (fr) * | 1991-12-30 | 1994-02-04 | Synthelabo | Nouveaux derives de 2-(tetrazol-5-yl)-(1,1'-biphenyle), leur preparation et leur utilisation comme intermediaires de synthese. |
US5240953A (en) * | 1992-01-30 | 1993-08-31 | Ortho Pharmaceutical Corporation | Substituted triazoles as angiotensin ii inhibitors |
US5312958A (en) * | 1992-01-31 | 1994-05-17 | Takeda Chemical Industries, Ltd. | Process for producing 4-bromomethylbiphenyl compounds |
DE4206043A1 (de) * | 1992-02-27 | 1993-09-02 | Bayer Ag | Sulfonylbenzyl-substituierte imidazole |
TW215434B (ko) * | 1992-03-07 | 1993-11-01 | Hoechst Ag | |
US5208235A (en) * | 1992-03-10 | 1993-05-04 | E. R. Squibb & Sons, Inc. | Indole- and benzimidazole-substituted imidazole derivatives |
US5208234A (en) * | 1992-03-10 | 1993-05-04 | E. R. Squibb & Sons, Inc. | Substituted imidazole phosphonic and phosphinic acid derivatives |
FR2689508B1 (fr) * | 1992-04-01 | 1994-06-17 | Fournier Ind & Sante | Derives de l'imidazole, leur procede de preparation et leur application en therapeutique. |
US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US5378704A (en) * | 1992-04-15 | 1995-01-03 | E. R. Squibb & Sons, Inc. | Non-peptidic angiotensin-II-receptor-antagonists |
US5294722A (en) * | 1992-04-16 | 1994-03-15 | E. R. Squibb & Sons, Inc. | Process for the preparation of imidazoles useful in angiotensin II antagonism |
US5214153A (en) * | 1992-04-23 | 1993-05-25 | Merck & Co., Inc. | Actinoplanes transformation process anti-hypertensive compound and method of use thereas |
US5218125A (en) * | 1992-04-23 | 1993-06-08 | Merck & Co., Inc. | Antihypertensive compound and method of use thereas |
US5217882A (en) * | 1992-05-18 | 1993-06-08 | Merck & Co., Inc. | Microbial transformation process for producing antihypertensive N2 -glucuronide products |
ATE199548T1 (de) * | 1992-06-02 | 2001-03-15 | Sankyo Co | 4-carboxyimidazolderivate als angiotensin-ii- antagonisten und ihre therapeutische verwendung |
US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
DE4221009A1 (de) * | 1992-06-26 | 1994-01-05 | Bayer Ag | Imidazolyl-substituierte Cyclohexanderivate |
EP0577023A3 (en) * | 1992-07-01 | 1996-12-18 | Hoechst Ag | Angiotensin-ii receptor-antagonists for the treatment of arrhythmices |
US5484955A (en) * | 1992-07-06 | 1996-01-16 | Takeda Chemical Industries, Ltd. | Tri-higher alkyl tin azide and its use |
GB9218449D0 (en) | 1992-08-29 | 1992-10-14 | Boots Co Plc | Therapeutic agents |
IT1255461B (it) * | 1992-07-28 | 1995-11-02 | Luso Farmaco Inst | Eteri di imidazoli ad attivita' a ii antagonista |
US5283241A (en) * | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5583130A (en) * | 1992-09-25 | 1996-12-10 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5317017A (en) * | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
DE69332736T2 (de) * | 1992-12-07 | 2004-03-25 | Eisai Co., Ltd. | Verfahren zur herstellung von imidazopyridinderivaten und zwischenprodukte |
DE4242459A1 (de) * | 1992-12-16 | 1994-06-23 | Merck Patent Gmbh | Imidazopyridine |
CZ283315B6 (cs) * | 1992-12-17 | 1998-02-18 | Sankyo Company Limited | Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují |
DE4302956A1 (de) * | 1993-02-03 | 1994-08-04 | Bayer Ag | Substituierte Imidazo(4,5-b)pyridine und Benzimidazole |
US5284841A (en) * | 1993-02-04 | 1994-02-08 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5514811A (en) * | 1993-02-15 | 1996-05-07 | Shikoku Chemicals Corporation | Process for synthesizing 4-halo-5-(hydroxymethyl) imidazole compounds |
DK0614890T3 (da) * | 1993-03-12 | 1997-10-13 | Lonza Ag | Fremgangsmåde til fremstilling af eventuelt 2-substituerede 5-chlorimidazoler. |
DE4308788A1 (de) * | 1993-03-18 | 1994-09-22 | Bayer Ag | Hetero-tricyclisch-substituierte Phenyl-cyclohexan-carbonsäurederivate |
CN1120837A (zh) * | 1993-04-07 | 1996-04-17 | 日产化学工业株式会社 | 吡唑衍生物 |
US5451597A (en) * | 1993-05-27 | 1995-09-19 | G.D. Searle & Co. | Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists |
LT3469B (en) | 1993-06-02 | 1995-10-25 | Chem Pharm Forsch Gmbh | Novel acylales of imidazol-5-carboxylic acid derivatives, process for their preparation and use thereof |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
WO1995001326A1 (en) * | 1993-06-30 | 1995-01-12 | The Wellcome Foundation Limited | Anti-atherosclerotic diaryl compounds |
US5610301A (en) * | 1993-07-01 | 1997-03-11 | American Cyanamid Company | Process for the regioselective n-alkylation of quinazolinones |
US5338740A (en) * | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
US5342944A (en) * | 1993-07-19 | 1994-08-30 | American Cyanamid Company | Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones |
US5298517A (en) * | 1993-10-07 | 1994-03-29 | American Cyanamid Company | Angiotensin II receptor blocking agents |
US5438136A (en) * | 1993-11-02 | 1995-08-01 | Merck & Co., Inc. | Benzo-fused macrocycles promote release of growth hormone |
US5606054A (en) * | 1993-12-14 | 1997-02-25 | Merck & Co., Inc. | Heterocyclic-fused lactams promote release of growth hormone |
WO1995024902A1 (fr) * | 1994-03-16 | 1995-09-21 | Sankyo Company, Limited | Reducteur de tension oculaire |
US5753672A (en) * | 1994-04-19 | 1998-05-19 | Tanabe Seiyaku Co., Ltd. | Imidazopyridine derivatives and process for preparing the same |
SE9502219D0 (sv) * | 1995-06-19 | 1995-06-19 | Astra Ab | Novel medical use |
PL324928A1 (en) * | 1995-08-10 | 1998-06-22 | Sumitomo Chemical Co | Derivatives of pyrimidin-4-one, their application, intermediate compounds for their production and methods of obtaining such intermediate compounds |
DK0853477T3 (da) * | 1995-10-06 | 2003-02-10 | Novartis Ag | AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer |
AU1791497A (en) | 1996-02-29 | 1997-09-16 | Novartis Ag | At1 receptor antagonist for the stimulation of apoptosis |
FR2753195B1 (fr) | 1996-09-09 | 1998-11-27 | Sanofi Sa | Procede pour la preparation d'un cyanobiphenyle |
JPH10203981A (ja) | 1997-01-21 | 1998-08-04 | Kureha Chem Ind Co Ltd | 心疾患改善剤 |
TW418204B (en) * | 1997-03-28 | 2001-01-11 | Dev Center Biotechnology | Novel 1,2,4-triazine-5-ketonyl benzene derivatives and the analogs, the preparation, and the pharmaceutical compositions as angiotension II receptor antogonists |
BR9908474A (pt) | 1998-03-04 | 2000-12-05 | Takeda Chemical Industries Ltd | Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica |
DE19820064A1 (de) * | 1998-05-06 | 1999-11-11 | Hoechst Marion Roussel De Gmbh | Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
DE69921124T2 (de) | 1998-06-12 | 2005-11-10 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Imidazolderivate und ihre verwendung als somatostatin rezeptorliganden |
DE19830431A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren |
US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
TR200805741T2 (tr) | 1998-12-23 | 2008-10-21 | Novartis Ag | At-1 veya at-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için at-1 reseptör antagonisti veya at-2 reseptör modülatörünün kullanımı@ |
CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
JP2003523330A (ja) | 2000-02-04 | 2003-08-05 | チルドレンズ・ホスピタル・リサーチ・ファウンデイション | アテローム性動脈硬化症および関連疾患のための脂質加水分解治療 |
AU7909801A (en) | 2000-08-01 | 2002-02-13 | Sod Conseils Rech Applic | Imidazolyl derivatives |
PE20020617A1 (es) | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
BR0102252B1 (pt) * | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
CA2466659A1 (en) | 2001-11-13 | 2003-05-22 | Takeda Chemical Industries, Ltd. | Anticancer agents |
AU2003234407B2 (en) | 2002-05-09 | 2008-12-18 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 as a cardiovascular disease marker and therapeutic target |
ATE388136T1 (de) | 2002-06-12 | 2008-03-15 | Sumitomo Chemical Co | Verfahren zur herstellung von 4'-brommethyl-2- cyanobiphenyl |
AU2003252259A1 (en) * | 2002-07-26 | 2004-02-16 | Nihon Nohyaku Co., Ltd. | Novel haloalkylsulfonanilide derivatives, herbicides and usage thereof |
DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
DE10306179A1 (de) | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
GB0316546D0 (en) | 2003-07-15 | 2003-08-20 | Novartis Ag | Process for the manufacture of organic compounds |
ES2567135T3 (es) | 2003-08-29 | 2016-04-20 | The Brigham And Women's Hospital, Inc. | Derivados de hidantoína como inhibidores de necrosis celular |
JP4537678B2 (ja) * | 2003-09-04 | 2010-09-01 | 住友化学株式会社 | 2’−(1h−テトラゾール−5−イル)ビフェニル−4−カルボアルデヒド結晶およびその製造方法 |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
JP4625812B2 (ja) | 2003-12-05 | 2011-02-02 | ザ クリーブランド クリニック ファウンデーション | 心臓血管疾患に対するリスクマーカー |
GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
EP1729749A2 (en) | 2004-03-17 | 2006-12-13 | Novartis AG | Use of renin inhibitors in therapy |
ITTO20040264A1 (it) * | 2004-04-28 | 2004-07-28 | Rotta Res Lab Spa | Nuovi derivati pirrolici ad attivita' angiotensina-ii antagonista |
EP1809759B1 (en) | 2004-10-06 | 2013-09-11 | The Brigham And Women's Hospital, Inc. | Relevance of achieved levels of markers of systemic inflammation following treatment |
WO2006038223A1 (en) * | 2004-10-06 | 2006-04-13 | Matrix Laboratories Ltd | A process for preparation of 2-n-butyl -4-chloro - 1 - {[2`- (2-triphenylmethyl - 2h - tetrazole - 5- yl) - 1, 1’ - biphenyl-4-yl] methyl}-lh- imidazoie-5-methanol (intermediate of losartan) |
KR20070101843A (ko) | 2004-10-08 | 2007-10-17 | 노파르티스 아게 | 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도 |
KR20070061583A (ko) | 2004-10-15 | 2007-06-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 텔미사르탄의 제조 방법 |
KR101021828B1 (ko) | 2004-10-27 | 2011-03-17 | 다이이찌 산쿄 가부시키가이샤 | 2 이상의 치환기를 갖는 벤젠 화합물 |
RU2412940C2 (ru) | 2005-02-03 | 2011-02-27 | Рациофарм Гмбх | Способ получения лосартана |
EP2808015A1 (en) | 2005-05-31 | 2014-12-03 | Mylan Laboratories, Inc | Compositions comprising nebivolol |
EP1752450A1 (en) | 2005-08-01 | 2007-02-14 | Merck Sante | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them |
WO2007026375A1 (en) | 2005-08-31 | 2007-03-08 | Suven Life Sciences | Process for the preparation of losartan |
US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
CN101024643A (zh) * | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
CN101085772A (zh) * | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
EP2924440A3 (en) | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
EP2103610B1 (en) | 2006-12-06 | 2011-09-21 | Shanghai Allist Pharmaceutical., Inc. | Salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof |
CN101214242A (zh) | 2007-01-05 | 2008-07-09 | 上海艾力斯医药科技有限公司 | 新的药用组合物 |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP2541254B1 (en) | 2007-04-18 | 2014-11-12 | Health Diagnostic Laboratory, Inc. | Diabetes-related biomarkers and methods of use thereof |
CN101172953B (zh) * | 2007-12-04 | 2011-12-28 | 王俊华 | 沙坦类治疗高血压药物替米沙坦中间体的制备方法 |
GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
US8236843B2 (en) * | 2008-09-02 | 2012-08-07 | Elder Pharmaceuticals Ltd. | Anti inflammatory compounds |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
JP2013518618A (ja) | 2010-02-01 | 2013-05-23 | ザ・ホスピタル・フォー・シック・チルドレン | 再狭窄を治療および予防するための遠隔虚血コンディショニング |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
SG10201908570RA (en) | 2010-03-31 | 2019-11-28 | Hospital For Sick Children | Use of remote ischemic conditioning to improve outcome after myocardial infarction |
AU2011237461B2 (en) | 2010-04-08 | 2015-11-26 | The Hospital For Sick Children | Use of remote ischemic conditioning for traumatic injury |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
PE20141049A1 (es) | 2011-04-12 | 2014-09-05 | Boryung Pharm | Composicion farmaceutica antihipertensiva |
CN106908604B (zh) | 2011-07-18 | 2019-01-29 | 重症监护诊断股份有限公司 | 治疗心血管疾病和预测运动疗法功效的方法 |
CN103012377A (zh) * | 2011-09-27 | 2013-04-03 | 江苏艾力斯生物医药有限公司 | 一种咪唑-5-羧酸酯的重结晶方法 |
BR112014014527A2 (pt) | 2011-12-15 | 2017-06-13 | Takeda Pharmaceuticals Usa Inc | combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros |
KR20130074808A (ko) | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
CN104136431B (zh) * | 2011-12-21 | 2017-03-15 | 小野药品工业株式会社 | 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物 |
MX361457B (es) | 2012-05-11 | 2018-12-06 | Reset Therapeutics Inc | Sulfonamidas que contienen carbazol como moduladoras de criptocromo. |
EP2879666B1 (en) | 2012-08-01 | 2020-04-08 | Tavakoli, Zahra | Free flowing, frozen compositions comprising a therapeutic agent |
JP2016514693A (ja) | 2013-03-15 | 2016-05-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハイブリッド型ネクロトーシス阻害剤 |
TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
WO2018043400A1 (ja) | 2016-08-30 | 2018-03-08 | 日本曹達株式会社 | スルホニルアミノベンズアミド化合物および有害生物防除剤 |
US10905676B2 (en) | 2017-07-07 | 2021-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2044754B (en) * | 1978-11-14 | 1983-05-05 | Eisai Co Ltd | Imidazoles |
JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
JPS57188570A (en) * | 1981-05-14 | 1982-11-19 | Shionogi & Co Ltd | Benzylazole derivative |
EP0142754A2 (en) * | 1983-11-04 | 1985-05-29 | Ferrer Internacional, S.A. | 2-Substituted-benzoic acid imidazoles, process for preparing them and pharmaceutical compositions containing them |
-
1987
- 1987-06-23 CA CA000540399A patent/CA1334092C/en not_active Expired - Lifetime
- 1987-07-09 ES ES87109919T patent/ES2063734T4/es not_active Expired - Lifetime
- 1987-07-09 NO NO872863A patent/NO176049C/no not_active IP Right Cessation
- 1987-07-09 EP EP87109919A patent/EP0253310B1/en not_active Expired - Lifetime
- 1987-07-09 DE DE1996175001 patent/DE19675001I2/de active Active
- 1987-07-09 AT AT87109919T patent/ATE113276T1/de active
- 1987-07-09 DE DE3750687T patent/DE3750687T2/de not_active Expired - Lifetime
- 1987-07-09 LU LU88662C patent/LU88662I2/fr unknown
- 1987-07-10 DK DK198703596A patent/DK174700B1/da not_active IP Right Cessation
- 1987-07-10 SU SU874203085A patent/SU1694062A3/ru active
- 1987-07-10 HU HU174/87A patent/HU218460B/hu unknown
- 1987-07-10 IE IE185287A patent/IE69984B1/en active Protection Beyond IP Right Term
- 1987-07-10 HU HU9902075A patent/HU218461B/hu unknown
- 1987-07-10 FI FI873071A patent/FI96025C/fi active Protection Beyond IP Right Term
- 1987-07-10 PT PT85312A patent/PT85312B/pt unknown
- 1987-07-10 AU AU75596/87A patent/AU599396B2/en not_active Expired
- 1987-07-10 IL IL83153A patent/IL83153A/xx not_active IP Right Cessation
- 1987-07-11 KR KR1019870007464A patent/KR900005020B1/ko not_active IP Right Cessation
-
1990
- 1990-02-23 KR KR1019900002283A patent/KR900005045B1/ko not_active IP Right Cessation
-
1993
- 1993-05-14 LV LV930351A patent/LV5486A3/xx unknown
-
1995
- 1995-04-11 HK HK55495A patent/HK55495A/xx not_active IP Right Cessation
- 1995-05-26 NO NO1995004C patent/NO1995004I1/no unknown
- 1995-06-07 NL NL950009C patent/NL950009I2/nl unknown
-
1996
- 1996-04-05 CY CY185596A patent/CY1855A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880001609A (ko) | 앤지오텐신 ii 수용체 차단 이미다졸 | |
KR920702681A (ko) | 치환된 이미다졸 | |
ES2207091T3 (es) | Acido imidazolil-alquenoico. | |
JP3231042B2 (ja) | 2−(2,6−ジ−ハロ−フェニルアミノ)フェニル酢酸の誘導体の硝酸エステルおよびその製造法 | |
KR920014805A (ko) | 퀴나졸리논 화합물, 그의 제약학적 조성물 및 그의 제조방법 | |
PT503785E (pt) | Derivados bifenilimidazole sua preparacao e sua utilizacao terapeutica | |
IE890045L (en) | Angiotensin ii receptor blocking imidazoles. | |
KR920019758A (ko) | 헤테로시클릭 치환 페닐아세트산 유도체, 그의 제조 방법 및 의약에서의 그의 용도 | |
CS9100906A2 (en) | Substituted azoles, method of their production, preparations that contain these compounds and their application | |
NL8702485A (nl) | Gesubstitueerde alfa-aminozuren, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten. | |
JP2015523980A5 (ko) | ||
KR890011854A (ko) | 안지오텐신 ⅱ 수용체 차단 이미다졸, 및 이뇨제 및 비스테로이드성 소염제와 이의 조성물 | |
KR20080006576A (ko) | 임의로 2-치환된1,6-디히드로-6-옥소-4-피리미딘카르복시산의 제조 방법 | |
SK13195A3 (en) | Imidazole carboxylic acids and pharmaceutical agent containing thereof | |
WO1992004335A2 (en) | Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension | |
KR910015546A (ko) | 복소환식 화합물 | |
SI9200240A (en) | New acylates from imidazole-5-carboxylic acid derivatives and process for their preparation and their use | |
JPS6220989B2 (ko) | ||
EP0531702B1 (en) | Process for the manufacture of insecticidal, nematicidal and acaricidal 2-aryl-3-subst. -5-(trifluoromethyl)pyrrole compounds from N-(subst. benzyl)-2,2,2-trifluoroacetimidoyl chloride compounds | |
CA2350031A1 (en) | N-arylsulfonylamino acid omega-amides | |
JP2011136905A (ja) | ベンゼン化合物及びその医薬用途 | |
JPS63275593A (ja) | β−アミノエチルリン酸エステル誘導体 | |
EP1000926A1 (en) | Process for making 2-(trihaloacetyl)-3-(substituted aminos)-2-propenoates | |
WO1992004330A1 (en) | Substituted imidazoles, their preparation and pharmaceutical compositions | |
JP6687477B2 (ja) | エステル化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20060711 Year of fee payment: 17 |
|
EXPY | Expiration of term |